<< Protein target for Parkinson's disease | Cellular and molecular mechanisms that accelerate the development and progression of atherosclerosis >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Dansk | Nederlands | Русский | Svenska | Polski

New alcohol biomarker test lowers the cost of caring for patients with chronic illnesses

Published on December 2, 2005 at 4:52 PM · No Comments

Adding a new alcohol biomarker test to patients' revelations about their drinking habits could lower the cost of caring for patients with chronic illnesses like diabetes and high blood pressure, a health economics analysis finds.

The alcohol-screening test measures the level of a chemical in the blood - carbohydrate deficient transferrin - which is responsive to alcohol. A cost-benefit analysis by Michael Fleming, M.D., and colleagues found that the CDT test increases the number of problem drinkers detected in a population of primary care patients.

The benefit-cost model - which uses data from surveys, published literature and two trials - is published in the November edition of the journal Alcoholism: Clinical and Experimental Research. The analysis estimates that CDT testing results in $212.30 in overall savings per patient by avoiding some medical and legal costs.

The alcohol biomarker is approved by the U.S. Food and Drug Administration, but Fleming said that many primary care physicians do not know about the CDT technology.

CDT is not a test for alcoholism; it can't judge whether a patient is dependent on alcohol, Fleming said. But the test can detect if a patient has consumed four to five alcoholic drinks a day within the last two weeks.

Once harmful drinking is identified through a CDT test, Fleming said a physician can try to rein in a patient's heavy alcohol consumption.

Heavy drinking can worsen illnesses like high blood pressure, diabetes and heart disease. Excessive alcohol consumption can also interfere with medications commonly prescribed for those conditions.

Peter Miller, a researcher at the Center for Drug and Alcohol Programs at the Medical University of South Carolina, is working to encourage more physicians to consider CDT in their care of patients who have alcohol-sensitive illnesses.

"You'd begin with a self-report questionnaire and then you might use the test for patients you suspect are heavier drinkers than they are admitting to," Miller said. "It's a more objective test that can corroborate what a patient or his family is saying."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading